Prior Authorization Required

Prior Authorization Required: Prior authorization may be required for automated insulin delivery (AID) systems depending on plan rules. Providers should submit PA requests when the member’s benefits require it and include documentation that the device is FDA cleared/approved for the patient’s age and indication.

• Prior authorization inference: Clinical trial inclusion criteria (age, duration of diabetes, stable insulin regimen) are reflected in the policy and may be used by plans to define PA requirements for type 2 diabetes (e.g., age ≥18; diagnosed ≥12 months; on MDI or pump ≥3 months; HbA1c ≥7% or clinically significant hypoglycemia).
• No explicit PA triggers in excerpt: The provided policy text does not list specific PA forms, codes, or stepwise authorization triggers; it describes medical-necessity criteria and documentation expectations instead.
• Device scope: Policy differentiates FDA cleared/approved AID systems (may be medically necessary when criteria met) versus non–FDA-cleared devices (considered experimental/investigational and not covered).
• Population scope: Criteria specified separately for type 1 and type 2 diabetes (type 1: FDA age requirement and pump education; type 2: hybrid closed-loop systems with age and treatment-history criteria).

Required Documentation and Denial Risk

Documentation and clinical justification are expected with PA submissions. The policy specifies required clinical elements for establishing medical necessity and indicates situations that increase denial risk.

• Required documentation: device FDA clearance/approval and patient age consistent with the device labeling; diabetes type (type 1 vs type 2) and duration; prior insulin therapy history (multiple daily injections >3x/day or insulin pump use and stability ≥3 months for type 2 trial-based criteria); recent HbA1c or history of significant hypoglycemia for type 2 criteria; evidence of comprehensive pump education within past 12 months for first-time pump users.
• Trial-based eligibility inference: Several pivotal trials used enrollment criteria (age ranges, duration of diabetes, stable insulin regimens, exclusion of recent severe hypoglycemia/DKA) — plans may use these trial criteria as a practical template for PA documentation.
• Monitoring recommended in studies: CGM metrics and HbA1c schedules used in trials (e.g., HbA1c measured every ~3 months; CGM time-in-range and percent time <70 mg/dL metrics) are relevant for ongoing device monitoring and documentation.
• Denial risk: Use of non–FDA-cleared AID systems is explicitly classified as experimental/investigational; failure to meet type 2-specific criteria (age, duration, prior insulin regimen, HbA1c/hypoglycemia status) creates denial risk.
• No documentation requirements specified: The excerpt does not provide a PA form, exact coding requirements, or a prescriptive list of operative PA fields (e.g., no explicit codes or PA form fields are listed).

Comparators, Evidence Context, and Data Considerations

Comparative and evidence-context notes — useful to support coverage discussions but not a substitute for PA documentation.

• Comparators noted: Sensor-augmented pumps, open-loop CGM plus pump, multiple daily injections — policy frames AID systems as alternatives or improvements to these comparators.
• Comparative study context only: Randomized trials and prospective studies summarized in the policy (RCTs and real-world large-series analyses) provide efficacy and safety context that may support medical necessity but do not define PA rules.
• Evidence exclusions: Studies with duplicative or overlapping populations were excluded from the evidence synthesis — reviewers should note potential gaps when relying on published cohorts (e.g., Forlenza et al. real-world dataset had data sufficiency requirements).
• Data sufficiency for inclusion (Forlenza et al.): Forlenza et al. required ≥90 days with ≥75% of days having ≥220 CGM readings/day to be included; real-world analyses like this can inform outcomes but are subject to dataset completeness requirements.

Operational Notes and Scope

Operational and scope clarifications for providers submitting PA or explaining coverage to members.

• Use in pregnancy: The policy does not address AID use in pregnancy; coverage for pregnant members should be determined by individual member contract benefits in effect at time of service.
• No step therapy rules in excerpt: The policy does not impose or describe any explicit step-therapy requirements or mandated prior therapies before AID system coverage.
• Prior therapy history: For type 2 coverage criteria and trial enrollment, documentation that the member has been on multiple daily injections (>3x/day) or pump therapy for the requisite duration (≥3 months) is relevant.
• No explicit PA rules provided: While plan-level PA may apply, this excerpt contains medical-necessity criteria and guidance rather than an explicit PA workflow or authorization criteria list; contact the payer’s PA department for operational PA requirements.